Literature DB >> 21911719

Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer.

Kathleen M Fairfield1, Kimberly Murray, F Lee Lucas, Heidi R Wierman, Craig C Earle, Edward L Trimble, Laurie Small, Joan L Warren.   

Abstract

PURPOSE: This analysis identifies factors associated with completion of adjuvant chemotherapy for patients with ovarian cancer and subsequent use of health services. PATIENTS AND METHODS: We used the Surveillance, Epidemiology, and End Results (SEER) -Medicare database to identify 4,617 women age 65 years or older with ovarian cancer diagnosed from 2001 to 2005. By using multivariable analyses with completion of chemotherapy as the outcome of interest, we describe factors associated with completion of treatment, including age, race, marital status, comorbidities, and sociodemographic factors. Use of health services was captured from Medicare claims.
RESULTS: Among 4,617 patients with untreated ovarian cancer, 1,329 (28.8%) received no chemotherapy, 1,139 (24.7%) received a partial course of chemotherapy, and 2,149 (46.5%) completed chemotherapy. Women age 75 years or older were at greater risk of incomplete chemotherapy versus women age 65 to 74 years (odds ratio [OR], 1.64; 95% CI, 1.33 to 2.04). Having two or more comorbidities was also significantly associated with incomplete chemotherapy (OR, 1.83; 95% CI, 1.34 to 2.50). Among women who received either a partial or complete course of chemotherapy, we did not find an increase in use of health services (hospitalizations, emergency department visits, or physician visits) for the oldest women (age 80 years or older) compared with younger women.
CONCLUSION: There is considerable room for improvement in helping older patients with ovarian cancer initiate and complete chemotherapy. The oldest women who completed chemotherapy in this study did not use health services more than younger women did. Treatment teams for older patients with ovarian cancer should include expertise in geriatric assessment, should carefully identify medical and psychosocial barriers to completing treatment, and should support patients throughout treatment.

Entities:  

Mesh:

Year:  2011        PMID: 21911719     DOI: 10.1200/JCO.2010.34.1552

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  14 in total

1.  Tolerability and Efficacy of Bevacizumab Monotherapy in Older Patients With Recurrent Ovarian Cancer.

Authors:  Daisuke Shintani; Hiroyuki Yoshida; Akira Yabuno; Keiichi Fujiwara
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Distinct Physical Function Profiles in Older Adults Receiving Cancer Chemotherapy.

Authors:  Christine Miaskowski; Melisa L Wong; Bruce A Cooper; Judy Mastick; Steven M Paul; Katherine Possin; Michael Steinman; Janine Cataldo; Laura B Dunn; Christine Ritchie
Journal:  J Pain Symptom Manage       Date:  2017-07-15       Impact factor: 3.612

3.  Assessment of solid cancer treatment feasibility in older patients: a prospective cohort study.

Authors:  Marie Laurent; Elena Paillaud; Christophe Tournigand; Philippe Caillet; Aurélie Le Thuaut; Jean-Léon Lagrange; Olivier Beauchet; Hélène Vincent; Muriel Carvahlo-Verlinde; Stéphane Culine; Sylvie Bastuji-Garin; Florence Canouï-Poitrine
Journal:  Oncologist       Date:  2014-02-25

4.  Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer.

Authors:  Tanya M Wildes; Alexander P Ruwe; Chloe Fournier; Feng Gao; Kenneth R Carson; Jay F Piccirillo; Benjamin Tan; Graham A Colditz
Journal:  J Geriatr Oncol       Date:  2013-07       Impact factor: 3.599

5.  Distinct attentional function profiles in older adults receiving cancer chemotherapy.

Authors:  Inger Utne; Borghild Løyland; Ellen Karine Grov; Hege Lund Rasmussen; Ann Helen Torstveit; Bruce A Cooper; Judy Mastick; Melissa Mazor; Melisa Wong; Steven M Paul; Yvette P Conley; Thierry Jahan; Christine Ritchie; Jon D Levine; Christine Miaskowski
Journal:  Eur J Oncol Nurs       Date:  2018-08-22       Impact factor: 2.398

6.  Combination chemotherapy with docetaxel and carboplatin for elderly patients with endometrial cancer.

Authors:  Hiroyuki Yoshida; Yuichi Imai; Keiichi Fujiwara
Journal:  Mol Clin Oncol       Date:  2016-02-16

7.  Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.

Authors:  Xianglin L Du; Rohan C Parikh; David R Lairson; Sharon H Giordano; Putao Cen
Journal:  Med Oncol       Date:  2013-01-10       Impact factor: 3.064

8.  Considerations regarding the administration of systemic therapy for elderly patients with ovarian cancer.

Authors:  William P Tew
Journal:  Curr Treat Options Oncol       Date:  2013-03

9.  A population-based observational study on the factors associated with the completion of palliative chemotherapy among patients with oesophagogastric cancer.

Authors:  Oliver Groene; Tom Crosby; Richard Henry Hardwick; Stuart Riley; Kimberley Greenaway; David Cromwell
Journal:  BMJ Open       Date:  2015-03-04       Impact factor: 2.692

Review 10.  Chemotherapy of ovarian cancer in elderly patients.

Authors:  Tiffany A Troso-Sandoval; Stuart M Lichtman
Journal:  Cancer Biol Med       Date:  2015-12       Impact factor: 4.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.